Cornerstone Investment Partners LLC acquired a new stake in shares of Organogenesis Holdings Inc. (NASDAQ:ORGO - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 50,502 shares of the company's stock, valued at approximately $162,000.
A number of other institutional investors have also recently made changes to their positions in the stock. Assenagon Asset Management S.A. boosted its stake in shares of Organogenesis by 54.0% during the fourth quarter. Assenagon Asset Management S.A. now owns 2,950,849 shares of the company's stock valued at $9,443,000 after purchasing an additional 1,035,120 shares during the period. State Street Corp boosted its stake in shares of Organogenesis by 0.6% during the third quarter. State Street Corp now owns 1,459,767 shares of the company's stock valued at $4,175,000 after purchasing an additional 9,090 shares during the period. Charles Schwab Investment Management Inc. boosted its stake in shares of Organogenesis by 2.6% during the third quarter. Charles Schwab Investment Management Inc. now owns 948,451 shares of the company's stock valued at $2,713,000 after purchasing an additional 23,675 shares during the period. Connor Clark & Lunn Investment Management Ltd. boosted its stake in shares of Organogenesis by 5.6% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 471,240 shares of the company's stock valued at $1,348,000 after purchasing an additional 24,878 shares during the period. Finally, Bank of New York Mellon Corp boosted its stake in shares of Organogenesis by 35.5% during the fourth quarter. Bank of New York Mellon Corp now owns 418,820 shares of the company's stock valued at $1,340,000 after purchasing an additional 109,762 shares during the period. Hedge funds and other institutional investors own 49.57% of the company's stock.
Organogenesis Trading Down 8.5 %
ORGO stock traded down $0.48 on Friday, reaching $5.16. The company's stock had a trading volume of 1,343,552 shares, compared to its average volume of 1,067,206. The business has a fifty day simple moving average of $3.65 and a two-hundred day simple moving average of $3.35. Organogenesis Holdings Inc. has a 12-month low of $2.17 and a 12-month high of $6.71. The firm has a market cap of $654.43 million, a PE ratio of -86.00 and a beta of 1.66. The company has a debt-to-equity ratio of 0.21, a quick ratio of 2.74 and a current ratio of 3.09.
Wall Street Analyst Weigh In
Separately, Morgan Stanley increased their price objective on Organogenesis from $4.00 to $6.00 and gave the company an "equal weight" rating in a research note on Wednesday.
Read Our Latest Report on Organogenesis
Insider Buying and Selling
In related news, Director Michael Joseph Driscoll sold 25,000 shares of the firm's stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $5.10, for a total value of $127,500.00. Following the completion of the sale, the director now owns 166,879 shares of the company's stock, valued at $851,082.90. This trade represents a 13.03 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Gary S. Gillheeney sold 157,448 shares of the firm's stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $3.64, for a total value of $573,110.72. Following the completion of the sale, the chief executive officer now directly owns 3,143,753 shares of the company's stock, valued at $11,443,260.92. The trade was a 4.77 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 284,700 shares of company stock valued at $1,051,472 over the last quarter. 36.90% of the stock is owned by company insiders.
About Organogenesis
(
Free Report)
Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.
Further Reading
Before you consider Organogenesis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Organogenesis wasn't on the list.
While Organogenesis currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for April 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
